Literature DB >> 21470343

Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus.

K Morikawa1, C M Lange, J Gouttenoire, E Meylan, V Brass, F Penin, D Moradpour.   

Abstract

Hepatitis C virus (HCV) nonstructural protein 3-4A (NS3-4A) is a complex composed of NS3 and its cofactor NS4A. It harbours serine protease as well as NTPase/RNA helicase activities and is essential for viral polyprotein processing, RNA replication and virion formation. Specific inhibitors of the NS3-4A protease significantly improve sustained virological response rates in patients with chronic hepatitis C when combined with pegylated interferon-α and ribavirin. The NS3-4A protease can also target selected cellular proteins, thereby blocking innate immune pathways and modulating growth factor signalling. Hence, NS3-4A is not only an essential component of the viral replication complex and prime target for antiviral intervention but also a key player in the persistence and pathogenesis of HCV. This review provides a concise update on the biochemical and structural aspects of NS3-4A, its role in the pathogenesis of chronic hepatitis C and the clinical development of NS3-4A protease inhibitors.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21470343     DOI: 10.1111/j.1365-2893.2011.01451.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  65 in total

1.  Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.

Authors:  Ann D Kwong; Robert S Kauffman; Patricia Hurter; Peter Mueller
Journal:  Nat Biotechnol       Date:  2011-11-08       Impact factor: 54.908

Review 2.  Regulation of hepatic innate immunity by hepatitis C virus.

Authors:  Stacy M Horner; Michael Gale
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

3.  The interdomain interface in bifunctional enzyme protein 3/4A (NS3/4A) regulates protease and helicase activities.

Authors:  Cihan Aydin; Sourav Mukherjee; Alicia M Hanson; David N Frick; Celia A Schiffer
Journal:  Protein Sci       Date:  2013-10-19       Impact factor: 6.725

Review 4.  Insights into antiviral innate immunity revealed by studying hepatitis C virus.

Authors:  Stacy M Horner
Journal:  Cytokine       Date:  2015-03-25       Impact factor: 3.861

Review 5.  Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies.

Authors:  José A Del Campo; Manuel Romero-Gómez
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

Review 6.  The ins and outs of hepatitis C virus entry and assembly.

Authors:  Brett D Lindenbach; Charles M Rice
Journal:  Nat Rev Microbiol       Date:  2013-09-10       Impact factor: 60.633

7.  Hepatitis C Virus Infection Is Inhibited by a Noncanonical Antiviral Signaling Pathway Targeted by NS3-NS4A.

Authors:  Christine Vazquez; Chin Yee Tan; Stacy M Horner
Journal:  J Virol       Date:  2019-11-13       Impact factor: 5.103

8.  Hepatitis C virus infects rhesus macaque hepatocytes and simianized mice.

Authors:  Margaret A Scull; Chao Shi; Ype P de Jong; Gisa Gerold; Moritz Ries; Markus von Schaewen; Bridget M Donovan; Rachael N Labitt; Joshua A Horwitz; Jenna M Gaska; Gabriela Hrebikova; Jing W Xiao; Brenna Flatley; Canny Fung; Luis Chiriboga; Christopher M Walker; David T Evans; Charles M Rice; Alexander Ploss
Journal:  Hepatology       Date:  2015-04-15       Impact factor: 17.425

Review 9.  Progress in the development of vaccines for hepatitis C virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Zahra Meshkat
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

10.  The linker region of NS3 plays a critical role in the replication and infectivity of hepatitis C virus.

Authors:  Andrew Kohlway; Nathan Pirakitikulr; Steve C Ding; Feng Yang; Dahai Luo; Brett D Lindenbach; Anna M Pyle
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.